2019-06 TRISCEND Study

NCT ID: NCT04221490

Last Updated: 2026-01-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

228 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-06

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a multi-center, prospective single arm study designed to evaluate the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tricuspid Valve Regurgitation Heart Valve Diseases Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Treatment with the Edwards EVOQUE Tricuspid Valve Replacement System

Group Type EXPERIMENTAL

Transcatheter Tricuspid Valve Replacement

Intervention Type DEVICE

Replacement of the tricuspid valve through a transcatheter approach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter Tricuspid Valve Replacement

Replacement of the tricuspid valve through a transcatheter approach

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Edwards EVOQUE Tricuspid Valve Replacement System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Functional or degenerative TR moderate or greater
* Symptomatic despite medical therapy or prior HF hospitalization from TR
* The Local Site Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement

Exclusion Criteria

* Tricuspid valve anatomic contraindications
* Need for emergent or urgent surgery or any planned cardiac surgery within the next 12 months
* Hemodynamic instability
* Refractory heart failure requiring advanced intervention
* Currently participating in another investigational study in which the patient has not reached a primary endpoint
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susheel Kodali, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Stanford University

Stanford, California, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status

Northwestern University

Evanston, Illinois, United States

Site Status

Massachusetts General Hospital Boston

Boston, Massachusetts, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Columbia University Irving Medical Center / NYPH

New York, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Baylor Heart Hopsital Plano

Plano, Texas, United States

Site Status

University of Virginia Health System

Charlottesville, Virginia, United States

Site Status

St. Paul's Hospital Vancouver

Vancouver, British Columbia, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-ULaval)

Québec, , Canada

Site Status

CHU Bordeaux, Hôpital Cardiologique Haut Lévêque

Pessac, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

InselSpital University Hospital Bern

Bern, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, Zahr F, Chadderdon S, Fam N, Ong G, Yadav P, Thourani V, Vannan MA, O'Neill WW, Wang DD, Tchetche D, Dumonteil N, Bonfils L, Lepage L, Smith R, Grayburn PA, Sharma RP, Haeffele C, Babaliaros V, Gleason PT, Elmariah S, Inglessis-Azuaje I, Passeri J, Herrmann HC, Silvestry FE, Lim S, Fowler D, Webb JG, Moss R, Modine T, Lafitte S, Latib A, Ho E, Goldberg Y, Shah P, Nyman C, Rodes-Cabau J, Bedard E, Brugger N, Sannino A, Mack MJ, Leon MB, Windecker S; the TRISCEND study investigators. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J. 2023 Dec 7;44(46):4862-4873. doi: 10.1093/eurheartj/ehad667.

Reference Type BACKGROUND
PMID: 37930776 (View on PubMed)

Kodali S, Hahn RT, George I, Davidson CJ, Narang A, Zahr F, Chadderdon S, Smith R, Grayburn PA, O'Neill WW, Wang DD, Herrmann H, Silvestry F, Elmariah S, Inglessis I, Passeri J, Lim DS, Salerno M, Makar M, Mack MJ, Leon MB, Makkar R; TRISCEND Investigators. Transfemoral Tricuspid Valve Replacement in Patients With Tricuspid Regurgitation: TRISCEND Study 30-Day Results. JACC Cardiovasc Interv. 2022 Mar 14;15(5):471-480. doi: 10.1016/j.jcin.2022.01.016.

Reference Type BACKGROUND
PMID: 35272771 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-06

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improve Sudden Cardiac Arrest Study
NCT02099721 COMPLETED NA
BioVentrix Revivent TC™ System Clinical Study
NCT02931240 ACTIVE_NOT_RECRUITING NA
The Jewel IDE Study
NCT05201495 COMPLETED NA
Extravascular ICD Pilot Study
NCT03608670 COMPLETED NA